亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Anti-Tuberculosis Compounds

總結
Novel Mycobacterium tuberculosis thioredoxin reductase inhibitors with antimycobacterial activity in infected macrophages that overcomes problems of current anti-tuberculotics.
技術優勢
Novel class of compounds that inhibit a novel target with potential to overcome resistance problems of M. tuberculosis to other drugs
Viability of infected macrophages is not affected
Increased bioactivity by optimized permeability through the cell wall of M. tuberculosis
技術應用
therapeutic development
詳細技術說明
The interaction between the mycobacterial thioredoxin reductase (TrxR) and its substrate thioredoxin (Trx) is a promising new drug target for the treatment of tuberculosis, since Mtb lacks the common glutathione system and the mycobacterial TrxR shows a substantial difference in sequence, mechanism and structure to human TrxRs. It was shown that TrxR is essential for thiol redox homeostasis and genetic inactivation in vivo eradicates Mtb during acute and chronic mouse infections. In order to further improve the bioactivity of promising compounds, researchershave focused on optimizing the physico-chemical properties that are important for permeability, since M. tuberculosis shows an unusual thick and impermeable cell wall.
合作類型
Licensing
申請日期
22/06/2018 00:00:00
申請號碼
WO2018EP66768 20180622
分類
- international:
A61K31/47; A61K31/4709; A61P31/06; C07D215/44; C07D215/46; C07D401/12; C07D413/12
- cooperative:
C07D215/44; C07D215/46; C07D401/12; C07D413/12
其他
Patent application
ID號碼
4941
國家/地區
德國

欲了解更多信息,請點擊 這裡
移動設備